Pages

Tampilkan postingan dengan label testing. Tampilkan semua postingan
Tampilkan postingan dengan label testing. Tampilkan semua postingan

Gay couples in Atlanta back HIV tests together


Some gay male couples, including ones in Atlanta and two other cities, support getting HIV tests with their partner as a way to bolster the relationship, but current testing protocols may not support it, according to a new study from Emory University researchers.

The study, “Attitudes Towards Couples-Based HIV Testing Among MSM in Three U.S. Cities,” was published in the journal AIDS and Behavior. Dr. Rob Stephenson of the Rollins School of Public Health at Emory worked with three colleagues from the school and others in Chicago and Seattle to complete the study. It calls on opening HIV testing to gay couples as a way to fill “a significant gap” in couples-based services for men who have sex with men (MSM) and to help them integrate routine HIV testing into their lives.

“Services remain individually focused,” the researchers say. “[Couples-based voluntary HIV counseling and testing] provides an opportunity for MSM to talk about sex, and to make plans for safer sexual behavior as a couple in the presence of a counselor.”

“The initial results presented here are encouraging. Couples-based voluntary HIV counseling and testing] is an acceptable format for HIV counseling and testing among MSM in this study, and if it is adapted and promoted well, could fill a significant gap in couples-based services for U.S. MSM,” they add.

The researchers launched the study after noting that heterosexual couples in Africa in which one member is HIV-positive and the other is not who receive HIV counseling and testing together helped bring about behavioral changes that reduced HIV transmission. So they examined attitudes toward couples-based testing with four focus groups of gay men in relationships in Atlanta, Chicago and Seattle.



[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Treatment as Prevention – The Tough Road Ahead


The sixth International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention started optimistically as the hype surrounding the use of antiretroviral treatment to prevent HIV infection gained momentum. But the focus of much discussion in Rome from 17-20 July will undoubtedly be on how to transform the recent promising research findings into workable policy.

The most significant of these is the HPTN052 randomized control trial, which found that earlier antiretroviral treatment can reduce the risk of heterosexual HIV transmission by as much as 96 percent; other studies have proven the efficacy of ARVs for prevention in HIV-negative people.

"We need to ensure that the advances we are making in research – such as the now proven concept of antiretroviral treatment as a means of HIV prevention – are translated into action for people in developing countries," said IAS local co-chair Stefano Vella, research director at Italy’s Istituto Superiore di Sanità, at the official opening of the conference.

But translating the research into action will require money, and if recent trends are any indication, that will be difficult, and there is much scepticism about the ability to significantly increase the numbers on treatment with such limited funds.

Donor pressure
"We need to keep up the pressure on donors... Donors are used to seeing costs rising year after year, but now we can show them a light at the end of the tunnel... We can show them that investing today will lead to lower costs tomorrow," Brenda Waning, coordinator of market dynamics with the health financing mechanism, UNITAID, said. "We also need to learn how to do more with limited resources."

Treatment as prevention will mean putting significantly more people on treatment earlier; at present, 15 million people are estimated to need ARVs – only 6.6 million have access to them.

"Treatment as prevention is possible, it is feasible, but we must not fool ourselves into thinking it's going to be easy," said Paul de Lay, deputy executive director of UNAIDS. "We put an additional 1.4 million new people on treatment in 2010 – if we maintain that momentum we will not achieve the goal of 15 million on treatment by 2015.

"We need to get to US$22 to $24 billion a year from the $15 billion a year we are currently spending; we need African governments to abide by the Abuja Declaration commitment to spend 15 percent of national budgets on health and we need donors to meet their commitments," he added.

"If we can convince donors that we can stop the epidemic within a finite amount of time, the money will be found," said Brian Williams, an epidemiologist with the UN World Health Organization (WHO).

Scaling-up HIV testing
Key to putting more people on treatment earlier will be finding those who need it; according to De Lay, most countries with hyper-endemic epidemics are testing just 4 percent of their populations.

Read the rest here.

[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

WHO Urges India to Address Medical Needs of Gay Men, Transgenders

Via The Hindu.

India must make an “extra effort” in addressing the medical needs of men who have sex with men (MSM) and transgender people affected by HIV and sexually-transmitted infections, a top WHO official said on Tuesday.

“Though India has addressed the HIV problem among MSM and transgender people, it has to make an extra effort in scaling up treatment and prevention services for HIV and sexually transmitted infections,” Dr. Gottfried Hirnschall, Director of HIV Department in World Health Organisation, told PTI.

In India, around 1.5 million transgender people and around 30.5 million MSM are vulnerable to the HIV and sexually-transmitted infections.

“In Asia, the odds of MSM being infected with HIV are 18.7 times higher than in the general population and the HIV prevalence ranges from 0 per cent to 40 per cent,” he said.

The WHO on Tuesday issued, for the first time, new public health recommendations to sensitise governments and health pressure groups in the developing world about the need to provide adequate medical treatment and prevention services to MSM and transgender people affected by HIV and sexually transmitted infections.

The guidelines call on governments to develop anti-discrimination laws and measures and provide more inclusive services for MSM and transgender people.

Health pressure groups must provide HIV testing and counselling followed by treatment for patients with CD4 count 350 or below.

Dr. Hirnschall said “criminalisation, and legal policy barriers play a key role in the vulnerability of MSM and transgender people to HIV.”

Read the rest here.

[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Annual HIV Testing May Not Suffice for MSM

Via CDC Morbidity and Mortality Weekly Report.

The findings from this analysis suggest that adherence to annual HIV testing recommendations for MSM is low and that even among MSM who reported being tested during the past 12 months, a substantial proportion were newly infected. Because persons often reduce their risk behaviors when they receive a diagnosis of HIV infection and persons who do not know they are infected are estimated to account for more than half of sexually transmitted HIV infections, increasing the frequency of HIV testing for MSM can reduce the time from HIV infection to diagnosis and reduce HIV transmission.

Current CDC guidelines identify MSM who should be tested more frequently according to their risk behaviors. However, among MSM in this analysis, those who had high-risk behaviors were not more likely to be newly infected than those without high-risk behaviors, suggesting that self-reported risk behaviors might not determine which MSM should be tested more frequently. The 7% prevalence of new HIV infection detected through NHBS among MSM who had been tested for HIV during the past year and the similar prevalence of new HIV infection among MSM with and without high-risk behaviors suggests that more frequent testing, perhaps as often as every 3 to 6 months, might be warranted among all sexually active MSM, regardless of their risk behaviors. In considering revising guidelines regarding frequency of testing among MSM, public health officials also should weigh other factors, including the acceptability and cost effectiveness of testing MSM more frequently and the sensitivity of tests in the early stages of infection.

Read the full report here.

[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]